Financing channel feed

Bill and Melin­da Gates Foun­da­tion backs lit­tle-known biotech go­ing af­ter Pfiz­er, Mer­ck on pneu­mo­coc­cal vac­cine

4 years ago

Low-pro­file eye drop de­vel­op­er spells out the game plan that drew Brent Saun­ders to the board — and it in­volves go­ing ear­li­er than an­ti-VEG­Fs

4 years ago

Feng Zhang’s qui­et spin­out snares $215M in a race for the next big CRISPR com­pa­ny

4 years ago
Cell/Gene Tx

A new Flag­ship start­up looks to crack tR­NA bi­ol­o­gy in search for com­plete­ly new class of ther­a­peu­tics

4 years ago
Startups

'We were wrong': Af­ter ush­er­ing Mer­ck KGaA in­to PD-(L)1 fren­zy, on­col­o­gy chief jumps on mis­sion to 'tur­bocharge' T cells

4 years ago
Cell/Gene Tx

Small biotech chaired by ex-Pur­due CEO Mark Tim­ney jumps in­to the SPAC lane

4 years ago

Cell ther­a­py start­up bit.bio adds $100M+ to its cof­fers and some im­pres­sive names to its board of di­rec­tors

4 years ago

A pair of Eu­ro­pean biotechs hit be­low their mark as close of 2021 biotech IPO mar­ket chugs a lit­tle bit slow­er

4 years ago

Tout­ing close ties to biotech in­cu­ba­tors, Mis­sion Bio­Cap­i­tal grabs $275M to help launch star­tups

4 years ago

Can new drugs punch holes in can­cer's pro­tec­tive bar­ri­er? For Parthenon Ther­a­peu­tics, that's the $65M ques­tion

4 years ago
Startups

An­tios Ther­a­peu­tic­s' hep B can­di­date gets an­oth­er round of ap­plause from in­vestors, clos­ing out a $171M megaround

4 years ago

CRISPR Ther­a­peu­tics co-founder un­cloaks an off-the-shelf cell ther­a­py start­up with $87M and a lot of fan­fare

4 years ago
Startups

Bay­er backs a George Church spin­out try­ing to turn lab-in­vent­ed amino acids in­to a new class of pro­tein ther­a­pies

4 years ago
Startups

Go­ing af­ter Hunt­ing­ton's dis­ease again, ex-Te­va R&D chief gets some cash for Prile­ni­a's re­newed ef­forts

4 years ago

Fresh off Kite and BeiGene deals, Shore­line ups the ante with a hefty crossover. But the biotech in­sists it's in no rush

4 years ago

Per­cep­tive steers Lian­Bio's glob­al­ly con­nect­ed Chi­na strat­e­gy to $325M IPO

4 years ago
China

In­tra­cel­lu­lar tar­gets, eye can­cer ther­a­py and light-ac­ti­vat­ed skin­care: Here's the lat­est on biotech IPOs

4 years ago

A pair of part­ners at Fra­zier is fol­low­ing ear­ly-stage biotechs to the pub­lic mar­ket with an $830M fund. And they're al­ready do­ing deals

4 years ago

Koch leads mam­moth $215M in­fu­sion in­to AI start­up boast­ing 'largest data­base' of im­mune cells

4 years ago
AI

Med­able trots its way to uni­corn sta­tus amid vir­tu­al tri­al craze. Is a pub­lic de­but next?

4 years ago

A qui­et car­dio up­start makes some noise, get­ting $300M from Bain and div­ing deep in­to the clin­ic — with some re­al mon­ey for pipeline deals

4 years ago

Mozart Ther­a­peu­tics makes its of­fi­cial de­but, jump­ing in­to the hot Treg R&D field with some big-name in­vestors back­ing it

4 years ago
Startups

Backed by Eli Cas­din, a DNA syn­the­sis com­pa­ny gets a big Se­ries C ahead of its first prod­uct launch

4 years ago

Brent Saun­ders joins $100M Se­ries C for a com­pa­ny out to be the Bridge­Bio of ag­ing

4 years ago
First page Previous page 63646566676869 Next page Last page
A service from the Financial Times